Trastuzumab Rezetecan (SHR-A1811)

DRUG2 trials

Sponsors

The First Affiliated Hospital of Soochow University, Sun Yat-sen University

Conditions

HER2-positive Breast CancerOvarian CancerPlatinum Sensitive Ovarian Cancer (PSOC)

Phase 2

Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer

RecruitingNCT07647263

The First Affiliated Hospital of Soochow UniversityHER2-positive Breast Cancer

Start: 2026-03-24End: 2031-12-01Target: 124Updated: 2026-06-15

Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Not yet recruitingNCT07776171

Sun Yat-sen UniversityOvarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)

Start: 2026-09-30End: 2030-05-30Target: 176Updated: 2026-08-20